Glenmark Pharmaceuticals has announced the launch of its Tiogiva tiotropium bromide DPI in the UK for the treatment of COPD. The company announced in August 2018 that it had acquired the rights to market the generic version of Spiriva Handihaler in Western Europe; the company also acquired the rights to market the Stalpex fluticasone/salmeterol DPI in Europe from Celon.
In addition to the launch of Tiogiva in the UK, Glenmark said that it plans to launch the inhaler in Ireland, Sweden, Finland and Norway under the same brand name. In Denmark, Spain and the Netherlands, the DPI will be called Tavulus; in Germany, it will be marketed as Tiotropium Glenmark.
Glenmark Pharmaceuticals EVP & Business Head of EMEA-L Achin Gupta commented, “We are glad to introduce Tiogiva, one of the first bioequivalent drugs to be launched in Europe for treatment of COPD. Respiratory medicine is a key area of focus for Glenmark and the launch of this product will enable us to improve access to COPD treatment by providing an effective and high quality treatment option to patients in UK and Western Europe.”
Read the Glenmark Pharmaceuticals press release.
